SPRONasdaqPharmaceutical PreparationsFiscal year ends December 31
Spero Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.12+0.02 (+1.82%)
Close on Oct 19, 2026
- Market cap
- $64.92M
- P/E (TTM)
- 28.0
- Dividend yield
- –
Spero Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Collaboration revenue - related party | $30.39M | $42.19M | $47.03M | $29.25M | $33.96M | $28.06M | $27.03M | 64.7% | -10.5% |
| Collaboration revenue | $12.57M | $12.57M | $12.59M | $64.00K | $129.00K | $243.00K | $371.00K | 26.8% | +9647.3% |
| Grant Revenue | $4.03M | $6.42M | $7.18M | $11.23M | $14.49M | $16.28M | $20.58M | 8.6% | -72.2% |
By region
From the segment and revenue-disaggregation notes of Spero Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.